3-(2-Methylbutan-2-yl)-1,2-oxazol-5-amine | 941867-85-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(2-Methylbutan-2-yl)-1,2-oxazol-5-amine
• CAS: 941867-85-2
• 化学式: C₈H₁₄N₂O
• mdl: MFCD09033870
• 分子量: 154.21
• InChiKey: KPFDFEIXPQVFPU-UHFFFAOYSA-N

物化性质

• 沸点：
  264.2±28.0 °C(Predicted)
• 密度：
  1.021±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Compounds Which Modulate The CB2 Receptor
  申请人：Berry Angela

  公开号：US20100009964A1

  公开（公告）日：2010-01-14

  Compounds of formula (I) are disclosed. Compounds according to the and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

  公式（I）的化合物已被披露。根据该公式的化合物对治疗炎症有用。那些是激动剂的化合物还额外适用于治疗疼痛。
• [EN] COMPOUNDS USEFUL FOR INHIBITING RET KINASE<br/>[FR] COMPOSÉS UTILES POUR INHIBER LA KINASE RET
  申请人：LILLY CO ELI

  公开号：WO2021222017A1

  公开（公告）日：2021-11-04

  Provided herein are RET kinase inhibitors according to the formula (I): pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.

  本文提供了根据公式（I）的RET激酶抑制剂，其药学上可接受的盐，药物组合物以及它们在治疗可用RET激酶抑制剂治疗的疾病中的使用方法，包括与RET相关的疾病和疾病。A、R1、n、X1、X2、X3、X4和R2在规范中给出了它们的含义。
• COMPOUNDS USEFUL FOR INHIBITING RET KINASE
  申请人：Eli Lilly and Company

  公开号：US20210363140A1

  公开（公告）日：2021-11-25

  Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R 1 , n, X 1 , X 2 , X 3 , X 4 , and R 2 have the meanings given in the specification.
• US8173638B2
  申请人：——

  公开号：US8173638B2

  公开（公告）日：2012-05-08